The glial response in Multiple System Atrophy (MSA) plays a crucial role in disease progression. Unlike Parkinson's disease where neuronal alpha-synuclein pathology is primary, MSA features prominent glial alterations that contribute to both oligodendrocyte dysfunction and neuronal degeneration.
MSA exhibits multiple glial abnormalities:
- Oligodendrocytes: Primary pathological target with GCI formation
- Microglia: Chronic activation, inflammatory cytokine release
- Astrocytes: Reactive changes, support dysfunction
The multi-glial involvement distinguishes MSA from typical synucleinopathies.
MSA is fundamentally an oligodendrogliopathy — a disease where oligodendrocytes are the primary target:
flowchart TD
A"Oligodendrocyte<br/>Stress" --> B"GCI Formation"
B --> C"Myelin<br/>Dysfunction"
C --> D"Axonal<br/>Degeneration"
D --> E"Secondary<br/>Neuronal Loss"
style A fill:#ffcdd2,stroke:#333
style C fill:#ffcdd2,stroke:#333
See: MSA oligodendrocyte pathology
| Factor |
Mechanism |
| High iron |
Oxidative stress, Fenton chemistry |
| Low antioxidant capacity |
Limited glutathione |
| High metabolic demand |
Myelin maintenance |
| Slow turnover |
Limited regeneration |
Microglia in MSA show:
- Chronic activation throughout affected regions
- Progressive proliferation (microgliosis)
- Pro-inflammatory phenotype (M1-like)
Activated microglia concentrate in:
- Striatonigral pathway — highest density
- Pontocerebellar white matter
- Autonomic nuclei
- Cerebral cortex (less severe)
MSA microglia release:
| Cytokine |
Level |
Effect |
| IL-1β |
↑↑ |
Pro-inflammatory |
| TNF-α |
↑↑ |
Neurotoxic |
| IL-6 |
↑ |
Inflammatory |
| TGF-β |
Variable |
Modulatory |
Microglial activation contributes to:
- Neuronal dysfunction — inflammatory mediators damage neurons
- Oligodendrocyte injury — cytokines promote GCI formation
- Blood-brain barrier dysfunction — allows peripheral immune access
- Alpha-synuclein spread — may facilitate prion-like propagation
Astrocytes in MSA show:
- Glial fibrillary acidic protein (GFAP) upregulation
- Morphological changes — hypertrophic processes
- Variable inclusion formation — less than oligodendrocytes
Astrocyte changes impair:
- Metabolic support — reduced lactate delivery to neurons
- Ion homeostasis — potassium buffering dysfunction
- Neurotransmitter clearance — glutamate uptake reduced
- Blood-brain barrier maintenance — endothelial support loss
| Glial Response |
MSA |
PD |
PSP |
| Oligodendrocyte GCI |
+++ |
- |
+ |
| Microglial activation |
++ |
++ |
++ |
| Astrocytic plaques |
- |
- |
+ (PSP) |
flowchart TD
subgraph "Inflammatory Cascade"
OLIGO"Oligodendrocyte<br/>GCI Stress" --> MG"Microglia<br/>Activation"
OLIGO --> ASTRO"Astrocyte<br/>Reactivity"
MG --> CYTO"Pro-inflammatory<br/>Cytokines"
ASTRO --> CYTO
CYTO --> NEURO"Neuronal<br/>Dysfunction"
end
style OLIGO fill:#ffcdd2,stroke:#333
style MG fill:#fff3e0,stroke:#333
style NEURO fill:#ffcdd2,stroke:#333
| Target |
Agent |
Status |
| Microglial activation |
Minocycline |
No clear benefit |
| Cytokine inhibition |
Anti-TNF |
Preclinical |
| Glial modulation |
Cannabis-derived |
Investigational |
- Blood-brain barrier limits drug delivery
- Microglial activation may have protective aspects
- Timing of intervention crucial
- CSF YKL-40 (chitinase-3-like protein): Elevated in MSA
- CSF IL-1β: Increased in active disease
- PET imaging: TSPO ligands show microglial activation
¶ Emerging Understanding
Recent research focuses on:
- Glial-neuronal crosstalk — bidirectional communication
- Network effects — how glial changes propagate
- Therapeutic targeting — specific glial populations
- Wenning et al., MSA as oligodendrogliopathy (2009)
- Stefanova et al., Microglial pathology in MSA (2005)
- Jellinger, Glial involvement in MSA (2014)
- Bicker et al., Neuroinflammation in MSA (2013)
- Papp et al., Glial inclusions in MSA (1989)